反相共流微流控毛细管装置制备高粘度水滴的方法

Executive Industry Relevance

Generating monodisperse high-viscosity droplets remains a persistent challenge in droplet-based applications, particularly for viscous formulations in drug delivery and materials synthesis. This phase-inversion co-flow method enables reliable production of uniform droplets from fluids exceeding 1 Pas viscosity, addressing a key bottleneck in handling high-viscosity actives and excipients. By leveraging initial low-viscosity droplet formation followed by controlled phase inversion, the approach improves process robustness and reproducibility for downstream biopharma workflows.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables encapsulation of high-viscosity bioactive compounds for screening assays requiring precise dosing.
• Operational Value: Facilitates formulation screening of viscous drug candidates without complex emulsification.

Screening & Assay Development

• Scientific Value: Produces monodisperse droplets ensuring consistent reaction kinetics in high-throughput screening.
• Operational Value: Supports standardized droplet generation for assay miniaturization and reagent conservation.

Translational & Preclinical Research

• Scientific Value: Allows preparation of uniform drug-loaded droplets for in vivo efficacy and pharmacokinetic studies.
• Operational Value: Enables scalable production of viscous formulations for preclinical toxicity and biodistribution testing.

Pipeline & Workflow Integration

The method fits within early discovery to preclinical stages, supporting hypothesis testing of viscous formulations and enabling standardized assay inputs for lead optimization.

• Discovery Biology: Supports interrogation of therapeutic hypotheses involving viscous macromolecules or nanoparticle suspensions.
• Screening: Delivers reproducible droplet sizes critical for comparing compound behavior across conditions.
• Analytics: Provides quantitative size and uniformity metrics to evaluate formulation performance.
• Translational Research: Connects discovery-stage droplet generation to preclinical continuity through consistent physicochemical properties.
• Enterprise Reuse: Offers a modular microfluidic platform adaptable to various high-viscosity systems across projects.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by reducing variability in droplet-based assays.
• Operational Value: Improves reproducibility and scalability of viscous fluid handling in microfluidic workflows.
• Strategic Value: Supports better go/no-go decisions by enabling reliable assessment of high-viscosity drug candidates.
• Portfolio Impact: Reduces late-stage formulation risk through early-stage de-risking of viscous active ingredients.

Implementation Considerations

• Requires expertise in microfluidic device assembly and surface treatment techniques.
• Depends on precision fluid control systems such as syringe pumps for flow rate regulation.
• Necessitates optical monitoring capabilities for droplet generation visualization and quality control.
• Involves material compatibility assessment for ODTS coating and epoxy sealing with target fluids.
• Limited by the need for immiscible fluid pairs and wettability control at the device exit.

Biopharma FAQs